…
|
Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=217716
Through a career spanning three decades and counting, Douglas Liu has managed various operations for life sciences companies in Boston, Chicago, Europe and Montgomery County. He has been involved with numerous organizations in the field, including the Tech Council of Maryland and the Governor’s International Advisory Council.
Such wide experience is a key reason he was recently chosen as board chairman of BioHealth Innovation, a Rockville-based public-private nonprofit that helps commercialize innovative ideas in the field and expand those companies. The partnership formed about two years ago after it was among the recommendations of the Montgomery County Biosciences Task Force.
BHI CEO Rich Bendis recently served as an expert panelist contributing to a special report from the “White House Lab-to-Market Inter-Agency Summit.” Panelists examined the U.S. federal government’s investment in drug R&D and the resulting private sector commercialization. According to the Summit report:
Federal research has done exceedingly well at accomplishing its original intent, which is to increase human knowledge, meet mission needs, and undertake high-risk research of long-term importance to the U.S. economy that is beyond the reach of the private sector. But commercialization of resulting discoveries from agency research has largely been an after-thought, despite clear Congressional and Presidential intent expressed through a series of legislative mandates and Executive Orders. While research to meet agency missions is critical, the members of the Panel believe that if the U.S. is to remain globally competitive in the 21st century, it must accelerate the translation of federally-funded R&D into commercial outcomes that create economic and public value, thus maximizing the return on the public dollars invested.
Read more at:
Increasing the Impact of Federally-Funded R&D
BHI Also Announces Agreement With BD to Create Entrepreneur-in-Residence Position
Rick Ivey, BD Diagnostics
BioHealth Innovation, Inc. (BHI) today announced the fiscal year 2013-2014 election of officers and a new appointment to its Board of Directors. BHI also announced it has entered into an agreement with BD (Becton, Dickinson and Company) to establish an entrepreneur-in-residence (EIR) position at the National Institutes of Health (NIH) Office of Technology Transfer. In conjunction with this agreement, BD is entitled to a voting position on the BHI Board of Directors, which will be held by Richard M. “Rick” Ivey, Worldwide Vice President Research & Development, BD Diagnostics – Diagnostic Systems.
“I am pleased to welcome the new roster of officers and a new member to the BHI Board of Directors,” said Richard Bendis, BHI President and CEO. “The officers are a committed group of individuals who already have contributed to the steady growth of BHI, and will continue to be important leaders as the organization further develops.”
“Rick Ivey joins the Board on behalf of BD as part of the terms of an agreement between BHI and BD to establish an NIH EIR position,” added Mr. Bendis. “He represents an important new addition to our Board as he is a seasoned medical technology executive who can offer experience and insights to the growing cadre of start-up diagnostics companies in the State of Maryland.”
|
As the Mid-Atlantic region’s premier accounting and consulting firm, Aronson LLC has built a tradition of excellence spanning 50 years. Hundreds of dedicated business experts provide innovative solutions designed specifically for each client. Aronson LLC specializes in comprehensive audit, tax and consulting services for clients ranging from individual taxpayers up through publicly traded companies poised for continued success. |
|
|
BD Diagnostics is a global leader of products and instruments used for diagnosing infectious diseases. Their products are used in the clinical market to screen for microbial presence, grow and identify organisms, and test for antibiotic susceptibility. In the industrial market, Diagnostic Systems’ products are used for the testing of sterile and non-sterile pharmaceuticals and medical devices, for environmental monitoring and to detect food pathogens. |
|
In 2012, Maryland ranked 5th in the number and total value of Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) program awards, after California, Massachusetts, Virginia and New York. Maryland firms received 265 awards valued at $94 million. A DBED analysis of SBIR/STTR Phase I and Phase II data shows that the number and value of awards decreased nationally in the last four years, and Maryland followed this trend. Even so, when compared to other states, Maryland consistently ranked within the top five recipients of SBIR/STTR awards in both the number and the dollar value of awards received.
MIMETAS today announces the appointment of Herbert L. Heyneker, Ph.D. as Chairman of the Board of Directors. Dr. Heyneker will be supporting MIMETAS in her mission to develop high-throughput Organ-on-a-Chip products for predictive therapy testing.
“Organ-on-a-Chip technology is extremely hot in the United States today. But none of the technologies I’ve seen so far comes even close to the level of elegance and sophistication that MIMETAS is offering.” says Herb Heyneker, who is based in the San Francisco Bay area. “I am strongly convinced that MIMETAS technology has the potential to create a revolution in medicine development and therapy selection. […]”
National Brain Tumor Society’s inaugural event draws over 100 brain tumor researchers, biopharma executives, government officials, and venture capital investors
National Brain Tumor Society, the largest nonprofit in the United States dedicated to the brain tumor community, recently hosted the inaugural Advancing Research to Therapies (ART) for Brain Tumors Conference in Washington, D.C. The ART Conference brought together more than 100 leading experts from academic research labs, government agencies, biotech and pharmaceutical companies, and venture capital firms to increase communication and collaboration, as well as discuss licensing and investment criteria for new drug candidates to speed the discovery of new treatments for brain tumor patients.
…
|
Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=238034